- Home
- SLG vs RARE Comparison
SLG vs RARE Comparison
Compare SLG & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | RARE |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.2B |
| IPO Year | 1997 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SLG | RARE |
|---|---|---|
| Price | $44.61 | $36.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 15 |
| Target Price | $59.12 | ★ $85.20 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $661,814,000.00 | $630,598,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | $9.94 | $20.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.63 |
| 52 Week Low | $40.26 | $25.81 |
| 52 Week High | $76.49 | $49.19 |
Technical Indicators
Market Signals| Indicator | SLG | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 61.44 |
| Support Level | $40.26 | $35.65 |
| Resistance Level | $45.39 | $36.74 |
| Average True Range (ATR) | 1.78 | 1.43 |
| MACD | 0.24 | 0.18 |
| Stochastic Oscillator | 56.13 | 53.64 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.